Activity

Full-scale aerobic granular sludge technology under the trade name Nereda® has been implemented for municipal, as well as industrial wastewater treatment. Owing to the operational reactor procedures, two types of waste aerobic granular sludge can be clearly distinguished 1) aerobic granular sludge selection discharge (AGS-SD) and 2) aerobic granular sludge mixture (AGS-RTC). This study systematically compared the anaerobic biodegradability of AGS-SD and AGS-RTC under mesophilic conditions. Results were further compared with the anaerobic conversion of waste activated sludge (WAS) as well as primary sludge (PS) from full-scale municipal wastewater treatment plants. Analysis showed similar chemical characteristics for AGS-SD and PS, which were both characterized by a high carbohydrate content (429 ± 21 and 464 ± 15 mg glucose/g VS sludge, respectively), mainly cellulosic fibres. Concurrently, AGS-RTC exhibited chemical properties close to WAS, both characterized by a relatively high protein content, which were individually 498 ± 14 and 389 ± 15 mg/g VS sludge. LY3522348 ic50 AGS-SD was characterized by a high biochemical methane potential (BMP) (296 ± 15 mL CH4/g VS substrate), which was similar to that of PS, and remarkably higher than that of AGS-RTC and WAS. Strikingly, the BMP of AGS-RTC (194 ± 10 mL CH4/g VS substrate) was significantly lower than that of WAS (232 ± 11 mL CH4/g VS substrate). Mechanically destroying the compact structure of AGS-RTC only accelerated the methane production rate but did not significantly affect the BMP value. Results indicated that compared to WAS, the proteins and carbohydrates in AGS-RTC were both more resistant to anaerobic bio-degradation, which might be related to the presence of refractory microbial metabolic products in AGS-RTC. Current methods for evaluating bovine viral diarrhea virus (BVDV) vaccination response typically rely on measurement of humoral responses as determined by virus neutralizing antibody titers (VNT) against BVDV. While VNT are correlated with increased protection, research has also shown that cell mediated immunity (CMI) is an important component of a protective response against BVDV. For example, improved protection against BVDV by modified-live viral (MLV) vaccines as compared to killed vaccines is thought to be due to better CMI induced by the MLV. The goal of this work was to evaluate the cell mediated response in vaccinated calves using a novel PrimeFlow RNA assay that incorporates cell surface marker staining with intracellular RNA expression of cytokines and viral RNA detection. Results from this study evaluating mRNA for IFN-γ and IL-2 at 24 h post-BVDV stimulation are similar to previous studies in which IFN-γ was detected in the CD4+ and CD8+ T cell population. However, a novel observation was the detection of IFN-γ mRNA in the NK cell population in vaccinated animals. The NK cell population contributed a significant portion of the IFN-γ produced. This study also demonstrated a decrease in the frequency and amount of BVDV in PBMCs, harvested from vaccinated calves and exposed to BVDV in vitro. Collectively data from this study highlights the association between an increase in IFN-γ and a decreased infection rate of isolated PBMC’s, based on the frequency and amount of BVDV positive cells following in vitro exposure. This new method combines not only the ability to evaluate cellular responses, but also the ability to understand potential antiviral properties associated with cellular responses. This is the first assay to describe and simultaneously measure CMI responses and intracellular viral RNA quantity as a method to evaluate protective responses associated with vaccination. Published by Elsevier B.V.Two experiments were conducted to test the effectiveness of a silicone matrix as an intravaginal drug delivery device for letrozole, an aromatase inhibitor used for synchronization protocols in cattle. A wax dip-coat formulation of the intravaginal device used in previous studies was effective in releasing letrozole but was cumbersome to manufacture and deploy, resulting in unwanted variation in drug delivery and circulating concentrations of letrozole. In Experiment 1, a 3 × 3 design was used to test the release kinetics of letrozole from silicone in vitro. Silicone was mixed with 3 different letrozole drug loads (5%, 10%, 15%) and 3 different mineral oil loads (5%, 10%, 15%), and letrozole release into 62.5% ethanol was compared with the wax dip-coat formulation (positive control) by UV spectrophotometry. Letrozole was released from silicone in a dose-dependent manner, with no effect of mineral oil. Release kinetics were then examined in vivo (Experiment 2) in nulliparous beef heifers assigned randomly to she 15% LSA groups. As well, the diameter profiles of the dominant follicle and the corpus luteum were largest (P  less then  0.01) in the positive control and 15% LSA groups. In conclusion, letrozole was released from a silicone matrix in vitro in a dose-dependent manner, and the 15% LSA devices achieved target effects on ovarian function. Results may be used to manufacture a silicone intravaginal device for delivering aromatase inhibitors in a novel synchronization protocol for cattle. Despite the potential of nanoparticle-based vaccines, their therapeutic efficacy for cancer immunotherapy is limited. To elicit robust antigen-specific adaptive immune responses, antigen-loaded nanoparticles are employed for transport into host dendritic cells (DCs); however, only a minority of the nanoparticles can be engulfed by host DCs. Herein, an injectable dual-scale mesoporous silica vaccine consisting of mesoporous silica microrods (MSRs) coupled with mesoporous silica nanoparticles (MSNs) is introduced. The MSRs form a three-dimensional macroporous scaffold after injection, and the subsequent release of DC-recruiting chemokine loaded in the mesopores of MSRs leads to the recruitment of numerous DCs into the scaffold. Subsequently, MSNs co-loaded with an antigen and Toll-like receptor 9 agonist, which exist in interparticle space of the MSR scaffold, are internalized by the recruited DCs, leading to the generation of antigen-presenting activated DCs. Strikingly, the MSR-MSN dual-scale vaccine generates a significantly larger number of antigen-specific T cells and inhibits melanoma growth to a greater extent compared with a single MSR or MSN vaccine.